Business Wire
02 Oct 2026, 06:30 UTC · 11h ago
Verdict
Headline takes no side. We score SMMT +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Summit Therapeutics, AstraZeneca, and Daiichi Sankyo entered a clinical trial collaboration to evaluate ivonescimab in combination with the TROP2-directed ADC Datroway.
Newannounced today in press release
So whatValidation by two global pharma giants likely increases the probability of success for SMMT's lead asset, potentially driving a re-rating of its valuation multiple.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The combination therapy will be tested across multiple solid tumor settings, specifically including breast and lung cancer.
Newannounced today in press release
More positive than 79% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Entering a clinical trial collaboration to evaluate a potential first-in-class drug combination.
More positive than 66% of ticker scores this week
Collaborating on clinical trials for a novel antibody drug conjugate combination.
More positive than 66% of ticker scores this week
Collaborating on clinical trials for a novel antibody drug conjugate combination.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
23h ago
More positive than 55% of relationship scores this week
[mutual] Summit Therapeutics entered into a clinical trial collaboration agreement with Daiichi Sankyo to evaluate ivonescimab in combination with Datroway.
More positive than 35% of relationship scores this week
[mutual] Daiichi Sankyo and AstraZeneca are joint collaborators in the clinical trial involving the combination of their respective therapies.
+1.3%
Price agrees with the score
$16.90 vs $16.69 close before publication (Oct 1) · not market-adjusted
SMMT chart →
